When the Heart Tries to Heal Itself

Leon Wirz
Apr 20
5 min read

Nature Communications, February 2026 | Shanghai Jiao Tong University & Tongji University

Introduction

Cardiovascular disease remains the leading cause of death worldwide, and its long-term burden is largely driven by a fundamental biological limitation: the human heart has only a very limited capacity to regenerate after injury.

When a myocardial infarction occurs, a substantial number of cardiomyocytes (specialized muscle cells responsible for contraction) are lost. Instead of being replaced, the damaged tissue is stabilized through fibrosis, a process in which scar tissue forms. While this prevents immediate structural failure, it reduces the heart’s functional capacity and often leads to progressive heart failure over time.

For decades, biology textbooks described the adult mammalian heart as a post-mitotic organ, meaning its cells are permanently withdrawn from the cell cycle. However, more recent findings have shown that a low level of cardiomyocyte turnover does exist, suggesting that regenerative capacity is not entirely absent, but rather tightly suppressed. This shifts the central scientific question: not whether the heart can regenerate, but why this ability is so limited, and whether it can be reactivated in a controlled way.

The Core Discovery

The study identifies a protein called RBM22 as a key regulator of cardiomyocyte proliferation and cardiac repair. Rather than introducing new regenerative mechanisms, RBM22 appears to act by removing barriers that prevent existing ones from functioning.

Mechanistically, RBM22 enables cardiomyocytes to re-enter the cell cycle by overcoming transcriptional and epigenetic constraints. In simple terms, it helps unlock genes that are necessary for cell division but are normally inaccessible in adult heart cells. This leads to increased proliferation and improved tissue repair following injury.

This is an important conceptual advance. The findings suggest that the inability of the adult heart to regenerate is not due to a lack of biological capability, but rather due to regulatory systems that actively suppress this capability.

How the Study Was Conducted

To investigate this mechanism, the researchers combined genetic, molecular, and functional approaches across multiple experimental systems.

In mouse models, they selectively deleted the gene encoding RBM22 in cardiomyocytes. These animals were then subjected to cardiac injury, either through myocardial infarction or surgical removal of heart tissue. In parallel, gene therapy experiments were conducted, where RBM22 was reintroduced using a viral delivery system to assess whether increasing its levels could enhance repair.

At the molecular level, techniques such as RNA sequencing and chromatin accessibility assays were used to understand how RBM22 influences gene expression. These were complemented by protein-DNA interaction studies, which allowed the researchers to determine where RBM22 binds in the genome.

To explore translational relevance, the study also included experiments in human induced pluripotent stem cell-derived cardiomyocytes, providing insight into whether similar mechanisms may operate in human cells.

Key Findings

Across all experimental systems, a consistent picture emerges. RBM22 is upregulated in response to cardiac injury and is particularly enriched in cardiomyocytes near the damaged region. This suggests that it is part of an endogenous response mechanism rather than an artificial intervention.

When RBM22 is absent, the consequences are pronounced. Cardiomyocyte proliferation is significantly reduced, fibrotic tissue formation increases, and overall cardiac function deteriorates. This is observed both in neonatal models, where regenerative capacity is naturally higher, and in adult models, where it is typically minimal.

At the mechanistic level, RBM22 directly activates a set of genes that are essential for cell cycle progression, including CDK4, Cyclin A2, and Cyclin E1. These genes are normally silenced in adult cardiomyocytes. RBM22 binds to their promoter regions and increases chromatin accessibility, effectively making these genes available for transcription.

This process is mediated through interaction with the chromatin remodeling protein SMARCA4. Together, they create a more open chromatin structure, allowing RNA polymerase II to access the DNA and initiate transcription. This epigenetic reactivation of cell cycle genes is a central mechanism through which RBM22 promotes regeneration.

Functionally, increasing RBM22 levels through gene therapy leads to measurable improvements. In mouse models of myocardial infarction, treated animals show increased cardiomyocyte proliferation, reduced scar formation, and improved cardiac performance. Importantly, similar proliferative effects are observed in human-derived cardiomyocytes, indicating that the mechanism is not species-specific, even though the human cells used are relatively immature.

Limitations of the Study

Despite the strength of the findings, several limitations must be considered. The majority of functional evidence comes from mouse models, which are known to differ from humans in their regenerative capacity, particularly during early development.

The human data relies on induced pluripotent stem cell-derived cardiomyocytes, which resemble immature heart cells and do not fully replicate the behavior of adult human cardiomyocytes. It remains uncertain whether the same degree of proliferative response can be achieved in fully mature human heart tissue.

In addition, the study does not address long-term outcomes. While short-term improvements in cardiac function are observed, the durability and safety of RBM22-mediated interventions remain unclear.

Relevance for Switzerland

From a healthcare systems perspective, the implications are significant. Cardiovascular disease represents one of the largest cost components within the Swiss healthcare system, both in terms of direct medical expenses and indirect costs such as loss of productivity and long-term disability.

Current therapies primarily focus on managing symptoms and preventing further deterioration. A therapy that enables even partial regeneration of heart tissue could fundamentally change this model. Instead of lifelong management, treatment could shift toward restoring function, potentially reducing the need for repeated hospitalizations, chronic medication, and advanced interventions such as heart transplantation.

For Switzerland’s pharmaceutical sector, this type of mechanism-based regenerative approach aligns with a broader strategic shift toward high-impact, curative therapies.

Potential Impacts of a Successful Therapy

If the mechanisms described in this study can be translated into clinical therapies, the impact would extend beyond cardiology. It would represent a broader shift in medicine from repair to regeneration.

In practical terms, this could mean that damage caused by heart attacks is no longer permanent. Patients might recover not just stability, but actual functional tissue. This would reduce long-term disease burden and alter the economic structure of treatment, moving away from continuous cost accumulation toward potentially one-time interventions.

Risks

At the same time, the risks associated with inducing cell proliferation must be taken seriously. Reactivating the cell cycle in cells that are normally non-dividing introduces the possibility of uncontrolled growth, which is a hallmark of cancer.

There are also structural considerations. The heart is a highly organized organ, and even small disruptions in cell architecture or electrical signaling can lead to arrhythmias. Ensuring that newly formed cells integrate correctly will be a major challenge.

Finally, gene therapy approaches themselves carry risks related to delivery, immune responses, and long-term genetic effects.

Overall Assessment

This study does not demonstrate that heart regeneration has been achieved in humans. However, it provides a detailed and convincing explanation of why regeneration is limited and identifies a mechanism through which this limitation can be overcome.

Its strength lies in connecting molecular biology with functional outcomes. By showing how a single regulatory factor can influence chromatin structure, gene expression, and ultimately organ-level repair, the study offers a coherent framework for future therapeutic development.

What Comes Next

Future research will need to focus on translating these findings into clinically viable strategies. This includes validating the mechanism in more physiologically relevant human models, developing safe delivery systems, and assessing long-term effects.

A central question remains whether it is possible to induce regeneration without triggering unwanted side effects such as tumor formation or functional instability. Addressing this balance will be critical for moving from experimental biology to clinical application.

Reference

Duan, X., Tan, Y., Zhang, Y. et al.

Restoration of RBM22 overcomes the transcriptional and epigenetic barriers of cardiomyocyte proliferation for heart regeneration.

Nat Commun (2026). https://doi.org/10.1038/s41467-026-70235-3